LifeStance Health Group announced a secondary public offering of 45 million shares priced at $13.12 each, with proceeds going to selling stockholders, not the company. LifeStance will repurchase 2 million shares from the underwriters at the same price, contingent on the offering's completion. The offering is expected to close around November 12, 2026, with Barclays and J.P. Morgan as underwriters. This move allows LifeStance to manage its stock structure while raising capital for selling shareholders without diluting existing shares.
LifeStance Health Group's stock is trading at USD 13.16 on Pluang, slightly above the secondary offering price of $13.12. The stock has seen a 4.43% decline in the last day. These figures are current as of Nov 09, 2026 21:11 WIB.
LifeStance Health Group, a major provider of outpatient mental health care, announced a secondary public offering of 45 million shares by existing stockholders, with the company itself not selling any shares or receiving proceeds. Concurrently, LifeS...
LifeStance Health reported a 25% increase in revenue to $455.9 million for Q3 2026, driven by higher visit volumes and clinician growth. Net income rose to $22.4 million from $1.1 million the previous year, with Adjusted EBITDA up 70% to $68.4 millio...
